- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Lilly pens $202M deal for preclinical DNA delivery biotech Engage as M&A streak continues | ||
| Mi | With $30M launch, Oorja Bio breathes new life into South Korean fibrosis candidate | ||
| Mi | Incyte pays Genesis $80M to expand AI-fueled drug discovery pact | ||
| Mi | Immunovant pays out $39M to call time on FcRn inhibitor after eye disease phase 3 fails | ||
| Mi | Parabilis, fresh from inking Regeneron pact, plans IPO to fund tumor drug's phase 3 push | ||
| Di | Incyte inks deal with Edison Scientific to train AI through drug discovery | ||
| Di | Merck inks Keytruda supply pact to support Exelixis' colorectal cancer trial | ||
| Di | Relay 'full steam ahead' on PI3K inhibitor fueled by first phase 2 data in blood vessel disorder | ||
| Mo | Sanofi and Wave post AATD updates in race to end genetic disease's 40-year new treatment drought | ||
| Mo | BioMarin's $270M Inozyme bet looks in trouble after rare disease drug misses key ph. 3 goal | ||
| Mo | After rare disease flop, cash-strapped Quince finds salvation in reverse merger | ||
| Mo | Nominations now open for Fierce Biotech's 2026 Fierce 15 | ||
| Mo | Vincentage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators | ||
| Mo | Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy | ||
| Mo | Ipsen unveils data for Botox rival that drove long-acting anti-wrinkle jab into phase 3 | ||
| Mo | Analysts 'shaking heads' after Regeneron melanoma drug fails to beat Keytruda in phase 3 trial | ||
| Fr | Novartis, amid reorg, cuts 'select number' of biomedical research roles | ||
| Fr | Alumis pulls back from would-be rival to Amgen's Tepezza after assessing prospects | ||
| Fr | Aardvark to dig into phase 3 data early after FDA imposes hold | ||
| 14.05. | Create Medicines fashions $122M fundraise for in vivo CAR-T dreams | ||
| 14.05. | Biogen advances Alzheimer's tau program despite midphase miss | ||
| 14.05. | Regenxbio reaps pivotal win for Duchenne muscular dystrophy gene therapy | ||
| 14.05. | Aptose, facing cash crunch, exits blood cancer pact after Hanmi buyout blocks development | ||
| 13.05. | With $1B Novo deal and diabetes ambitions undimmed, Lexicon is in 'good shape to go crazy' | ||
| 13.05. | Fosun pays $60M for option on AriBio's phase 3 Alzheimer's asset |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.